Firms
Cormorant Asset Management
- Founded
- —
- Type
- Venture capital
Funds0
No funds on record yet.
Team
No team members on record yet.
Co-investing
ARCH Venture PartnersAspen Neuroscience$115M · 2025-11-20
Aspen Neuroscience$115M · 2025-11-20nChroma$75M · 2024
Rapport Therapeutics$150M · 2023-08-23
Chroma Medicine$135M · 2023-03-01
Rapport Therapeutics, Inc.$150M · 2023
Prime Medicine, Inc.$200M · 2021-07-13
Epirium Bio$85M · 2019-12-18
Scholar Rock$36M · 2016-01-04Rapport$150M · Unknown date
Prime Medicine, Inc.$— · Unknown date
Volastra Therapeutics$60M · Unknown date
Volastra Therapeutics$44M · Unknown date
Quanterix$46M · Unknown date
Parabilis Medicines$305M · Unknown date
Bain CapitalFreenome$254M · 2024-02-15
AdaRx Pharmaceuticals$200M · 2023-08-09
Adarx$46M · 2023
JenaValve$100M · 2022-08-31
JenaValve Technology$100M · 2022-08-31
JenaValve Technology$100M · 2022
Interius BioTherapeutics$76M · 2021-05-18
InflaRX$55M · 2017-10-13
Solid Biosciences$50M · 2017
Replimune$55M · Unknown date
Replimune Group$55M · Unknown date
Abcuro$200M · Unknown date
Quanterix$46M · Unknown date
T. Rowe Price
Rapport Therapeutics$150M · 2023-08-23
AdaRx Pharmaceuticals$200M · 2023-08-09
Adarx$46M · 2023
Rapport Therapeutics, Inc.$150M · 2023Rapport$150M · Unknown date
Prime Medicine, Inc.$— · Unknown date
Atlas Venture
nChroma$75M · 2024
Chroma Medicine$135M · 2023-03-01
Antares Pharma$177M · Unknown date
Replimune$55M · Unknown date
Replimune Group$55M · Unknown date
Casdin CapitalnChroma$75M · 2024
Chroma Medicine$135M · 2023-03-01
Prime Medicine, Inc.$200M · 2021-07-13
Prime Medicine, Inc.$— · Unknown date
Gimv
JenaValve$100M · 2022-08-31
JenaValve Technology$100M · 2022-08-31
ImmunOs$74M · 2022-06-08
JenaValve Technology$100M · 2022
Omega Funds
JenaValve Technology$100M · 2022-08-31
Antares Pharma$177M · Unknown date
Replimune$55M · Unknown date
Replimune Group$55M · Unknown date
Andera Partners
JenaValve$100M · 2022-08-31
JenaValve Technology$100M · 2022-08-31
JenaValve Technology$100M · 2022
F-Prime Capital
nChroma$75M · 2024
Prime Medicine, Inc.$200M · 2021-07-13
Prime Medicine, Inc.$— · Unknown date
Foresite Capital
Solid Biosciences$50M · 2017
Replimune$55M · Unknown date
Replimune Group$55M · Unknown date
Logos Capital
Rapport Therapeutics$150M · 2023-08-23
Rapport Therapeutics, Inc.$150M · 2023Rapport$150M · Unknown date
OrbiMed
Aspen Neuroscience$115M · 2025-11-20
AdaRx Pharmaceuticals$200M · 2023-08-09
Adarx$46M · 2023
Polaris Partners
Scholar Rock$36M · 2016-01-04
Volastra Therapeutics$60M · Unknown date
Volastra Therapeutics$44M · Unknown date
Qatar Investment Authority
JenaValve$100M · 2022-08-31
JenaValve Technology$100M · 2022-08-31
JenaValve Technology$100M · 2022
RA Capital Management
InflaRX$55M · 2017-10-13
Solid Biosciences$50M · 2017
Parabilis Medicines$305M · Unknown date
Samsara BioCapital
ImmunOs$74M · 2022-06-08
Prime Medicine, Inc.$200M · 2021-07-13
Abcuro$200M · Unknown date
Axon Partners Group
Aspen Neuroscience$115M · 2025-11-20
Aspen Neuroscience$115M · 2025-11-20
Catalio Capital Management
Volastra Therapeutics$60M · Unknown date
Volastra Therapeutics$44M · Unknown date
DCVCFreenome$254M · 2024-02-15
Chroma Medicine$135M · 2023-03-01
Fidelity Investments
Rapport Therapeutics$150M · 2023-08-23
Scholar Rock$36M · 2016-01-04
Forbion
Replimune$55M · Unknown date
Replimune Group$55M · Unknown date
Kite, a Gilead Company
Aspen Neuroscience$115M · 2025-11-20
Aspen Neuroscience$115M · 2025-11-20
Lifeforce Capital
Aspen Neuroscience$115M · 2025-11-20
Aspen Neuroscience$115M · 2025-11-20
Lightspeed
ImmunOs$74M · 2022-06-08
Antares Pharma$177M · Unknown date
Osage University Partners
Chroma Medicine$135M · 2023-03-01
Interius BioTherapeutics$76M · 2021-05-18
S32Aspen Neuroscience$115M · 2025-11-20
Aspen Neuroscience$115M · 2025-11-20
Sofinnova Partners
Rapport Therapeutics, Inc.$150M · 2023Rapport$150M · Unknown date
SR One
AdaRx Pharmaceuticals$200M · 2023-08-09
Adarx$46M · 2023
The Goldman Sachs Group, Inc.
Rapport Therapeutics$150M · 2023-08-23
Rapport Therapeutics, Inc.$150M · 2023
Venrock Healthcare Capital Partners
AdaRx Pharmaceuticals$200M · 2023-08-09
Adarx$46M · 2023
Wellington Management
nChroma$75M · 2024
Chroma Medicine$135M · 2023-03-01
Abingworth LLP
Antares Pharma$177M · Unknown date
Adams Street Partners
Epirium Bio$85M · 2019-12-18
Agent Capital
Interius BioTherapeutics$76M · 2021-05-18
Alphabet Inc.
Parabilis Medicines$305M · Unknown date
Andreessen Horowitz (a16z) Bio + Health
Freenome$254M · 2024-02-15
Avon Ventures
Aspen Neuroscience$115M · 2025-11-20
Bain Capital Ventures
Quanterix$46M · Unknown date
BECO Capital
Scholar Rock$36M · 2016-01-04
BioMed Ventures
ImmunOs$74M · 2022-06-08
Bluebird Ventures
Epirium Bio$85M · 2019-12-18
BrightEdge
Interius BioTherapeutics$76M · 2021-05-18
Dementia Discovery FundJenaValve$100M · 2022-08-31
Eli Lilly and Company
Volastra Therapeutics$60M · Unknown date
Fidelity Management & Research Company
Rapport$150M · Unknown date
GV
Prime Medicine, Inc.$200M · 2021-07-13
Hercules Capital, Inc.
Quanterix$46M · Unknown date
Knollwood Investment Advisory
Interius BioTherapeutics$76M · 2021-05-18
Longitude Capital
Epirium Bio$85M · 2019-12-18
Longwood Fund
Interius BioTherapeutics$76M · 2021-05-18
Mass General Brigham Ventures
Abcuro$200M · Unknown date
Mission BioCapital
ImmunOs$74M · 2022-06-08
Moore Strategic Ventures
Prime Medicine, Inc.$200M · 2021-07-13
Newpath Partners
Prime Medicine, Inc.$200M · 2021-07-13
Perceptive Advisors
Solid Biosciences$50M · 2017
PSP Investments
Prime Medicine, Inc.$200M · 2021-07-13
Public Sector Pension Investment Board
Prime Medicine, Inc.$— · Unknown date
Pura Vida Investments
Freenome$254M · 2024-02-15
Redmile Group
Prime Medicine, Inc.$200M · 2021-07-13
Roche Venture Fund
Freenome$254M · 2024-02-15
Sanofi Ventures
Abcuro$200M · Unknown date
Section 32
Aspen Neuroscience$115M · 2025-11-20
Soleus Capital
Parabilis Medicines$305M · Unknown date
T. Rowe Price Associates
Prime Medicine, Inc.$200M · 2021-07-13
Tenmile
Antares Pharma$177M · Unknown date
The Kraft Group
Scholar Rock$36M · 2016-01-04
Vertex Ventures HC
Epirium Bio$85M · 2019-12-18
Vi Partners
JenaValve Technology$100M · 2022